Celgene Corporation (CELG) is set to announce its Q116 earnings before the market open on Thursday. Analysts expect the biotech firm to report earnings per share of $1.29 and revenue of $2.59 billion. That would be $0.11 higher the $1.18 per share posted last quarter, and $0.22 higher the $1.07 posted in the Q115. Revenue is projected to be $510 million higher than the $2.08 billion posted in the same period a year earlier. Meanwhile, EarningsWhisper.com reports a whisper number of $1.31 per share.
As a quick reminder, Celgene reported Q415 EPS of $1.18, $0.04 lower than the Street’s consensus estimate of $1.22. Revs increased 21.53% year-over-year to $2.54 billion versus the $2.54 billion consensus.
CELG shares have advanced 5.99% in the last 4 weeks and 3.75% in the past three months. Over the past 5 trading sessions the stock has lost 0.54%. The Palo Alto-based company, currently valued at $82.97 billion, has a median Street price target of $135.00 with a high target of $163.00.
CELG is down 6.49% year-over-year and 11.36% year-to-date.